Fredrick Chite Asirwa: International Cancer Institute clinic is recruiting breast cancer patients for clinical trials currently
Fredrick Chite Asirwa, CEO/Executive Director of International Cancer Institute, posted on LinkedIn:
“To contribute to science, quality, and outcomes of care to breast cancer patients, the International Cancer Institute clinic is recruiting breast cancer patients for clinical trials currently. Please email [email protected] or call +254 768 616 668 to check if you are eligible for the trials.
1. Breast Cancer clinical trial
A phase III, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of adjuvant atezolizumab or placebo and trastuzumab emtansine for her2-positive breast cancer at high risk of recurrence following preoperative therapy.
Inclusion Criteria:
a) Histologically confirmed invasive breast carcinoma
b) Confirmed human epidermal growth factor receptor 2 (HER2)-positive invasive breast cancer
c) Clinical stage at disease presentation Stage IIB-III (prior to neoadjuvant therapy): cT4/any N/M0, any cT/N2-3/M0, or cT1-3/N0-1/M0)
d) Pre-operative systemic chemotherapy MUST include at least 3 cycles of trastuzumab
2. Breast Cancer clinical trial
A Phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant in combination with phesgo versus phesgo after induction therapy with phesgo +/- taxane in patients with previously untreated HER2-positive, estrogen receptor-positive locally-advanced or metastatic breast cancer
Inclusion Criteria:
a) Histologically confirmed and documented human epidermal growth factor receptor 2 (HER2)-positive/estrogen receptor (ER)-positive adenocarcinoma of the breast with metastatic or locally-advanced disease not amenable to curative resection
b) Maintenance Phase Inclusion Criteria: Complete a minimum of four cycles of induction therapy, Achieve a minimum of stable disease (SD)
3. Breast Cancer clinical trial (Upcoming)
Multicenter, randomized, double-blind study of RO7247669 combined with nab-paclitaxel compared with pembrolizumab combined with nab-paclitaxel in participants with previously untreated, PD-L1 positive, locally-advanced unresectable or metastatic triple-negative breast cancer (stage IV TNBC)
Inclusion Criteria:
a) Metastatic or locally advanced unresectable, histologically documented TNBC (absence of HER2-over-expression, ER, and PgR expression)
b) No prior systemic therapy for metastatic or locally advanced unresectable TNBC. Previous, Prior early stage treatments completed more than 12 months ago, are allowed.
c) Tumor PD-L1 expression (PD-L1 positive). ”
Source: Fredrick Chite Asirwa/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023